Paediatric Hepatic International Tumour Trial
Studying Hepatoblastoma
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- University of Birmingham
- Principal Investigator
- Madhumita Dandapani, MD PhDUniversity of Nottingham
- Intervention
- Cisplatin(drug)
- Enrollment
- 450 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- St. Anna Kinderspital, Vienna, Austria
- Cliniques Universitaires Saint-Luc, Brussels, Woluwe-Saint-Lambert, Belgium
- University Hospital Motol, Prague, Czechia
- Kuopio University Hospital, Kuopio, Finland
- CHU de Rennes, Rennes, France
- Ludwig-Maximillians-University Munich, Munich, Germany
- Children's Health Ireland Crumlin, Dublin, Ireland
- Schneider Children's Medical Center, Petah Tikva, Israel
- Prinses Maxima Center, Utrecht, Netherlands
- Oslo University Hospital, Nydalen, Norway
- Medical University of Gdansk, Gdansk, Poland
- University Hospital Reina Sofia, Córdoba, Spain
- Hopitaux Universitaires de Geneve, Geneva, Switzerland
- Royal Aberdeen Children's Hospital, Aberdeen, United Kingdom
- Royal Belfast Hospital for Sick Children, Belfast, United Kingdom
- +15 more locations on ClinicalTrials.gov
Collaborators
Fundació Institut Germans Trias i Pujol · University Hospital Munich · University Hospital, Bonn · University of Kiel · University Hospital Tuebingen · University of Padova · Ludwig-Maximilians - University of Munich · Medical University of Gdansk · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Motol University Hospital · Rennes University Hospital · Children's University Hospital, Ireland · University of Oslo · Princess Maxima Center for Pediatric Oncology · Andaluz Health Service · Swiss Pediatric Oncology Group · Gothia Forum - Center for Clinical Trial · The Leeds Teaching Hospitals NHS Trust · Bambino Gesù Hospital and Research Institute · Newcastle University Centre for Cancer, Newcastle · Experimental Cancer Medicine Centres · XenTech, Evry
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03017326 on ClinicalTrials.govOther trials for Hepatoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188311Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenSun Yat-sen University
- RECRUITINGNCT05556642Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium InitiativeChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE1, PHASE2NCT04634357ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaEureka Therapeutics Inc.
- RECRUITINGPHASE2NCT07300449A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and AdolescentsSun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04901702Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT04478292A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyShanghai Children's Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT00980460Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerNational Cancer Institute (NCI)